Du är här

2014-04-23

MorphoSys AG: MorphoSys to Host Q1 2014 Conference Call on 29 April 2014

MorphoSys AG / MorphoSys to Host Q1 2014 Conference Call on 29 April 2014.
Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is
solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first
three months' 2014 results on 29 April 2014 at 7:00 am CEST.

At 2:00 pm CEST (1:00 pm BST, 8:00 am EDT), the Management Board of MorphoSys
AG will host a public conference call to present MorphoSys's financial
results for the first three months of 2014 and provide further details on the
Company's latest developments.

Dial-in numbers (listen only):

Germany: +
49 89 2444 32975

United Kingdom: +
44 20 3003 2666

USA:
+1 202 204 1514

An audio replay and manuscripts of the conference will be available
onwww.morphosys.com/conference-callsin due course.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 80 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,
visithttp://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®,arYla
®, Ylanthia®and 100 billion high potentials®are registered trademarks of
MorphoSys AG.

Slonomics®is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties. Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications&IR

Mario Brkulj
Associate Director Corporate Communications&IR

Alexandra Goller
Specialist Corporate Communications&IR

Jessica Rush
Specialist Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

Media Release (PDF)
http://hugin.info/130295/R/1778676/607522.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire

HUG#1778676

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.